Evolocumab limits adverse cardiovascular outcomes among PCI patients -

Treatment with evolocumab (Repatha), a common PCSK9 inhibitor, can help patients with a history of percutaneous coronary intervention (PCI) lower their risk of a major cardiovascular event, according to new findings published in Circulation: Cardiovascular Interventions.[1] “Patients who have undergone PCI...